<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869619</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0352</org_study_id>
    <nct_id>NCT03869619</nct_id>
  </id_info>
  <brief_title>REal World Data in LYmphoma and Survival in Adults</brief_title>
  <acronym>REALYSA</acronym>
  <official_title>REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas
      designed to enrich prognostic data, by integrating together epidemiological, clinical and
      biological data.

      REALYSA is a platform perfectly set up to

        -  Study prognostic factors using integrated epidemiological and biological data
           (genetics), to better characterize the determinants of refractoriness and relapse in
           patients with lymphoma, to follow the growing number of survivors and describe median to
           long-term sequela, second cancer, quality of life (QoL)â€¦

        -  Document treatment effectiveness in real life and observance

        -  Address socio-economical questions
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Years</target_duration>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients included per month in total and according to subtype of lymphoma</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in each region in total and according to subtype of lymphoma</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Survival</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Anti-Lymphoma Treatment (TTNLT)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Anti-Lymphoma Treatment (TTNLT)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Survival after progression</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Survival after progression</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Lymphoma transformations</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Lymphoma transformations</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Second cancers</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Second cancers</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of other chronic disease</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of other chronic disease</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exposure factors</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of comorbidities</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Representativeness of the included population</measure>
    <time_frame>5 years</time_frame>
    <description>Study population must show a good representativeness of the source population regarding demographic or diseases characteristics, to be able to generalize our results. Indeed, the representativeness of the study population can only be evaluated in areas covered by population-based cancer registries (PBCR) by comparing cases included in the REALYSA project to incident lymphoma cases registered in the general population (PBCR of the FRANCIM network).</description>
  </other_outcome>
  <other_outcome>
    <measure>Representativeness of the included population</measure>
    <time_frame>9 years</time_frame>
    <description>Study population must show a good representativeness of the source population regarding demographic or diseases characteristics, to be able to generalize our results. Indeed, the representativeness of the study population can only be evaluated in areas covered by population-based cancer registries (PBCR) by comparing cases included in the REALYSA project to incident lymphoma cases registered in the general population (PBCR of the FRANCIM network).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Diffuse Large B Lymphoma (DLBCL)</condition>
  <condition>Follicular Lymphoma (FL)</condition>
  <condition>Mantle Cell Lymphoma (MCL)</condition>
  <condition>Marginal Zone Lymphoma (MZL)</condition>
  <condition>T-cell Lymphoma (T-NHL)</condition>
  <condition>Hodgkin's Lymphoma (HL)</condition>
  <condition>Burkitt Lymphoma (BL))</condition>
  <arm_group>
    <arm_group_label>All enrolled patients</arm_group_label>
    <description>All patient who signed the consent form for participation to the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Real-life epidemiological platform of lymphoma in France</intervention_name>
    <description>The REALYSA database will be described with the following characteristics:
Number of patients included per month in total and according to subtype of lymphoma
Number of patients in each region in total and according to subtype of lymphoma</description>
    <arm_group_label>All enrolled patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with lymphoma in the last 6 months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of the consent form for participation in the REALYSA cohort

          -  Aged over 18 at the time of inclusion

          -  Diagnosed with lymphoma in the last 6 months (180 days)

          -  Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse
             large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone
             lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma

        Exclusion Criteria:

          -  Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids,
             vincristine, cyclophosphamide, etoposide, alone or in combination)

          -  Documented HIV infection

          -  Any other lymphoma subtype not included in the list in Appendix 1. Of note, are
             excluded:

               -  Chronic lymphocytic leukemia/small lymphocytic lymphoma

               -  Hairy cell leukemia and variant

               -  Lymphoplasmacytic lymphoma

               -  WaldenstrÃ¶m macroglobulinemia

               -  Primary DLBCL of the central nervous system (CNS)

               -  T-cell large granular lymphocytic leukemia

               -  Chronic lymphoproliferative disorder of NK cells

               -  Mycosis fungoides

               -  SÃ©zary syndrome

               -  Primary cutaneous T cell lymphomas (mainly diagnosed and treated by
                  dermatologists)

               -  Post-transplant lymphoproliferative disorders (PTLD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HervÃ© GhesquiÃ¨res, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Monnereau, MD</last_name>
    <role>Study Director</role>
    <affiliation>UniversitÃ© de Bordeaux : Inserm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HervÃ© GhesquiÃ¨res, MD</last_name>
    <phone>04 78 86 43 40</phone>
    <phone_ext>+33</phone_ext>
    <email>herve.ghesquieres@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain Monnereau, MD</last_name>
    <phone>05 56 33 33 33</phone>
    <phone_ext>+33</phone_ext>
    <email>A.Monnereau@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut BergoniÃ©</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fontanet BIJOU, MD</last_name>
      <phone>05 56 33 33 39</phone>
      <phone_ext>+33</phone_ext>
      <email>f.bijou@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Fontanet BIJOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Francois MITTERRAND</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CÃ©dric ROSSI, MD</last_name>
      <phone>03 80 29 50 41</phone>
      <phone_ext>+33</phone_ext>
      <email>cedric.rossi@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>CÃ©dric ROSSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD VendÃ©e</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadine MORINEAU, MD</last_name>
      <phone>02 51 44 61 73</phone>
      <phone_ext>+33</phone_ext>
      <email>nadine.morineau@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Nadine MORINEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Haut-LÃ©vÃªque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamal-Krimo BOUABDALLAH, MD</last_name>
      <phone>05 57 65 65 11</phone>
      <phone_ext>+33</phone_ext>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Kamal-Krimo BOUABDALLAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HervÃ© GhesquiÃ¨res, MD</last_name>
      <phone>04 78 86 43 40</phone>
      <phone_ext>+33</phone_ext>
      <email>herve.ghesquieres@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alain Monnereau</last_name>
      <phone>05 56 33 33 33</phone>
      <phone_ext>+33</phone_ext>
      <email>A.Monnereau@bordeaux.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>HervÃ© GhesquiÃ¨res, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <phone>03 88 12 76 79</phone>
      <phone_ext>+33</phone_ext>
      <email>luc-matthieu.fornecker@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LoÃ¯c YSEBAERT, MD</last_name>
      <phone>05 31 15 63 51</phone>
      <phone_ext>+33</phone_ext>
      <email>ysebaert.loic@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>LoÃ¯c YSEBAERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>real life</keyword>
  <keyword>cohort</keyword>
  <keyword>epidemiology</keyword>
  <keyword>PRO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

